Guardant Reveal aids organ preservation in rectal cancer treatment
PALO ALTO, Calif. - Guardant Health , Inc. (NASDAQ: NASDAQ:GH), a precision oncology company with a market capitalization of ...
Targeted Oncology16h
Nivolumab Plus Chemo Improves OS in Chinese Patients With Advanced Gastric/GEJ Cancer
The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and ...
oncnursingnews16h
Long-Term Survival Benefit Seen With Nivolumab Plus Chemo in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer
Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.